Article
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
Gynecologic oncology - 1 Apr 2015
Growdon Whitfield B, Groeneweg Jolijn, Byron Virginia, DiGloria Celeste, Borger Darrell R, Tambouret Rosemary, Foster Rosemary, Chenna Ahmed, Sperinde Jeff, Winslow John, Rueda Bo R
Abstract excerpt
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab binding site may confer resistance. The objective of this investigation was to characterize the expression of the p95HER2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
